Evidence map›Paper›PMID 27080012›Full record

ArticleExperimental hematology2016

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome.

Lacramioara Botezatu, Lars C Michel, Hideki Makishima, Thomas Schroeder, Ulrich Germing, Rainer Haas, Bert van der Reijden, Anne E Marneth, Saskia M Bergevoet, Joop H Jansen and 20 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Presence of theFrontiers in oncology · 2022
    Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 11 institutions in 7 countries.

Lacramioara BotezatuDepartment of Hematology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Lars C MichelDepartment of Hematology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Hideki MakishimaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, OH, USA.
Thomas SchroederDepartment of Hematology and Oncology, University Hospital Düsseldorf, Düsseldorf, Germany.
Ulrich GermingDepartment of Hematology and Oncology, University Hospital Düsseldorf, Düsseldorf, Germany.
Rainer HaasDepartment of Hematology and Oncology, University Hospital Düsseldorf, Düsseldorf, Germany.
Bert van der ReijdenDepartment of Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Anne E MarnethDepartment of Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Saskia M BergevoetDepartment of Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Joop H JansenDepartment of Laboratory Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Bartlomiej PrzychodzenDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, OH, USA.
Marcin WlodarskiDivision of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany.
Charlotte NiemeyerDivision of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany.
Uwe PlatzbeckerDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
Gerhard EhningerDepartment of Internal Medicine I, University Hospital TU Dresden, Dresden, Germany.
Ashwin UnnikrishnanLowy Cancer Research Centre and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.
Dominik BeckLowy Cancer Research Centre and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.
John PimandaLowy Cancer Research Centre and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.
Eva Hellström-LindbergCenter for Hematology and Regenerative Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Luca MalcovatiDepartment of Molecular Medicine, University of Pavia, and Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Jacqueline BoultwoodNuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
Andrea PellagattiNuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
Elli PapaemmanuilCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom.
Philipp Le CoutreMedical Department with Focus on Hematology/Oncology Charite Berlin, Campus Virchow-Klinikum, Berlin, Germany.
Jaspal KaedaMedical Department with Focus on Hematology/Oncology Charite Berlin, Campus Virchow-Klinikum, Berlin, Germany.
Bertram OpalkaDepartment of Hematology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Tarik MöröyInstitut de Recherches Cliniques de Montréal (IRCM), Hematopoiesis and Cancer Research Unit, and Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, Canada.
Ulrich DührsenDepartment of Hematology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Jaroslaw MaciejewskiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland, OH, USA.
Cyrus KhandanpourDepartment of Hematology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany. Electronic address: Cyrus.Khandanpour@uk-essen.de.
Radboud University Medical Center · NLHeinrich Heine University Düsseldorf · DEUNSW Sydney · AUCharité - Universitätsmedizin Berlin · DETU Dresden · DEUniversity of Freiburg · DEUniversity of Oxford · GBIstituti di Ricovero e Cura a Carattere Scientifico · ITKarolinska University Hospital · SEMontreal Clinical Research Institute · CAWellcome Sanger Institute · GB

Funding

CIHR MOP-111011CIHR MOP-84238
6 · The paper itself

Abstract

Inherited gene variants play an important role in malignant diseases. The transcriptional repressor growth factor independence 1 (GFI1) regulates hematopoietic stem cell (HSC) self-renewal and differentiation. A single-nucleotide polymorphism of GFI1 (rs34631763) generates a protein with an asparagine (N) instead of a serine (S) at position 36 (GFI1(36N)) and has a prevalence of 3%-5% among Caucasians. Because GFI1 regulates myeloid development, we examined the role of GFI1(36N) on the course of MDS disease. To this end, we determined allele frequencies of GFI1(36N) in four independent MDS cohorts from the Netherlands and Belgium, Germany, the ICGC consortium, and the United States. The GFI1(36N) allele frequency in the 723 MDS patients genotyped ranged between 9% and 12%. GFI1(36N) was an independent adverse prognostic factor for overall survival, acute myeloid leukemia-free survival, and event-free survival in a univariate analysis. After adjustment for age, bone marrow blast percentage, IPSS score, mutational status, and cytogenetic findings, GFI1(36N) remained an independent adverse prognostic marker. GFI1(36S) homozygous patients exhibited a sustained response to treatment with hypomethylating agents, whereas GFI1(36N) patients had a poor sustained response to this therapy. Because allele status of GFI1(36N) is readily determined using basic molecular techniques, we propose inclusion of GFI1(36N) status in future prospective studies for MDS patients to better predict prognosis and guide therapeutic decisions.

Indexed as

AllelesPolymorphism, Single NucleotideAdultAgedAmino Acid SubstitutionBiomarkersBone MarrowCohort StudiesCytogenetic AnalysisDNA-Binding ProteinsFemaleGene FrequencyGenotypeHumansMaleMiddle AgedBiomarkersDNA-Binding ProteinsGFI1 protein, humanTranscription Factors

Identifiers

PMID27080012
PMCPMC4917888
OpenAlexW2334189786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.